

Program	Indication	Trial name/ collaborator	Preclinical	Phase 1	Phase 2	Phase 3	Commercial rights	China NDA submission	U.S. NDA submission
Late stage	Plinabulin	CIN (All cancer, all chemo)	PROTECTIVE-1 (Study 105)	Phase 3 primary endpoint met at interim analysis			Global <sup>1</sup>	Q1 2020	H1 2020
	Plinabulin + pegfilgrastim		PROTECTIVE-2 (Study 106)	Phase 3 primary endpoint met at interim analysis					
	Plinabulin + docetaxel	NSCLC (2nd/3rd line)	DUBLIN-3 (Study 103)	Phase 3 second interim analysis completed			Global <sup>1</sup>	H2 2020	H1 2021
Investigator-initiated IO	Plinabulin + nivolumab	NSCLC (2nd/3rd line)	Fred Hutch/Univ. Washington/UCSD				Global <sup>1</sup>		
	Plinabulin + nivolumab + ipilimumab	SCLC	Rutgers University				Global <sup>1</sup>		
	Plinabulin + PD-1/PD-L1 + radiation/chemo	Multi-cancer (2nd/3rd line)	MD Anderson				Global <sup>1</sup>		
Other oncology pipeline	Protein degradation (molecular glue)	1st Target KRAS				Global <sup>1</sup>			
	BPI-002	Oral T cell co-stimulator				Global <sup>1</sup>			
	BPI-003	IKK inhibitor				Global <sup>1</sup>			
	BPI-004	Oral neo-antigen generator				Global <sup>1</sup>			